Peptides are increasingly used in wellness treatments despite a lack of robust clinical evidence, prompting debate over FDA advisory committee recommendations to allow their compounding.
Key facts
- •The unregulated peptide market is estimated to be worth between $100 million and $3 billion.
- •The FDA advisory committee recommended adding six experimental peptides to its compounding list, rejecting only one.
- •Most research on these peptides is limited to animal studies, with no large-scale human clinical trials.
- •Some online-purchased peptides have been found to contain lead or bacterial contamination.
- •The FDA has approved more than 40 peptide drugs for therapeutic use over the past decade.
Peptides are increasingly offered at wellness spas and clinics to treat conditions ranging from aging to injury, despite a lack of rigorous clinical evidence. An unregulated market estimated between $100 million and $3 billion has emerged, leading to concerns about safety and contamination. Recently, a US Food and Drug Administration (FDA) advisory committee recommended allowing select pharmacies to compound several experimental peptides, a move that could increase their availability.
By the numbers
Regulatory Grey Zones and Safety Risks
Most peptides sold online are classified as experimental compounds for research rather than approved medications. Because they are not regulated as drugs, they exist in a grey zone similar to supplements, where suppliers can sell them legally provided they make no health claims. Experts warn this environment poses significant risks, including potential contamination with lead or bacteria, and inconsistent dosing.
FDA Advisory Committee Recommendations
The FDA advisory committee recommended adding six experimental peptides—BPC-157, KPV, TB-500, MOTs-C, Semax, and epitalon—to its compounding list. If the FDA adopts this recommendation, it would allow select pharmacies to manufacture these compounds. While supporters argue this brings the substances under better regulatory oversight, critics contend it falsely implies the compounds have been proven safe and effective for human use.
Lack of Clinical Data
There is currently no rigorous clinical trial data confirming the efficacy or safety of these peptides in humans. Most existing research is based on animal studies, such as investigations into MOTs-C for metabolic health or TB-500 for tissue regeneration. Researchers emphasize that these findings do not equate to human safety, and the long-term side effects, optimal dosages, and administration frequencies remain unknown.
Advertisement
This article was independently rewritten by ManyPress editorial AI from reporting originally published by New Scientist.
